BSX250502P87000
- 0.15
- 0.000.00%
Boston Scientific Newsroom
Wells Fargo Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $118
Nephron Research Adjusts Boston Scientific Price Target to $125 From $120
A Quick Look at Today's Ratings for Boston Scientific(BSX.US), With a Forecast Between $110 to $125
Boston Scientific Is Maintained at Overweight by Barclays
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Encompass Health (EHC) and Integer Holdings (ITGR)
Needham Maintains Buy on Boston Scientific, Raises Price Target to $115
Barclays Raises Price Target on Boston Scientific to $125 From $118
Boston Scientific Is Maintained at Buy by Truist Securities
Boston Scientific Price Target Raised to $112.00/Share From $110.00 by Evercore ISI Group
Evercore ISI Group Maintains Outperform on Boston Scientific, Raises Price Target to $112
Boston Scientific Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Boston Scientific (BSX)
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $115
BTIG Maintains Boston Scientific(BSX.US) With Buy Rating, Raises Target Price to $124
RBC Raises Price Target on Boston Scientific to $120 From $116
Boston Scientific's Strong Financial Performance and Promising Outlook Support Buy Rating
Evercore ISI Adjusts Boston Scientific Price Target to $112 From $110, Maintains Outperform Rating
Research Alert: Boston Scientific Reports Strong Q1 Earnings With 26% Cardiovascular Growth
Jefferies Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $120
TD Cowen Maintains Boston Scientific(BSX.US) With Buy Rating, Maintains Target Price $115